Beck JF - Search Results

1

Histone deacetylase inhibitors require caspase activity to induce apoptosis in lung and prostate carcinoma cells.

Sonnemann J, Hartwig M, Plath A, Saravana Kumar K, Müller C, Beck JF. Sonnemann J, et al. Among authors: beck jf. Cancer Lett. 2006 Feb 8;232(2):148-60. doi: 10.1016/j.canlet.2005.02.009. Cancer Lett. 2006. PMID: 16458111

2

Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel.

Sonnemann J, Gekeler V, Ahlbrecht K, Brischwein K, Liu C, Bader P, Müller C, Niethammer D, Beck JF. Sonnemann J, et al. Among authors: beck jf. Cancer Lett. 2004 Jun 25;209(2):177-85. doi: 10.1016/j.canlet.2004.02.001. Cancer Lett. 2004. PMID: 15159020

3

Down-regulation of protein kinase Ceta potentiates the cytotoxic effects of exogenous tumor necrosis factor-related apoptosis-inducing ligand in PC-3 prostate cancer cells.

Sonnemann J, Gekeler V, Sagrauske A, Müller C, Hofmann HP, Beck JF. Sonnemann J, et al. Among authors: beck jf. Mol Cancer Ther. 2004 Jul;3(7):773-81. Mol Cancer Ther. 2004. PMID: 15252138

4

Apoptotic responsiveness of PC-3 prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand: evidence for differential effects of Bcl-xL and Bcl-2 down-regulation.

Sonnemann J, Gekeler V, Sagrauske A, Müller C, Hofmann HP, Beck JF. Sonnemann J, et al. Among authors: beck jf. Int J Oncol. 2004 Oct;25(4):1171-81. Int J Oncol. 2004. PMID: 15375570

5

Histone deacetylase inhibitors interact synergistically with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to induce apoptosis in carcinoma cell lines.

Sonnemann J, Gänge J, Kumar KS, Müller C, Bader P, Beck JF. Sonnemann J, et al. Among authors: beck jf. Invest New Drugs. 2005 Mar;23(2):99-109. doi: 10.1007/s10637-005-5854-9. Invest New Drugs. 2005. PMID: 15744585 Review.

6

Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.

Sonnemann J, Kumar KS, Heesch S, Müller C, Hartwig C, Maass M, Bader P, Beck JF. Sonnemann J, et al. Among authors: beck jf. Int J Oncol. 2006 Mar;28(3):755-66. Int J Oncol. 2006. PMID: 16465382

7

Histone deacetylase inhibitors induce cell death in supratentorial primitive neuroectodermal tumor cells.

Kumar KS, Sonnemann J, Beck JF. Kumar KS, et al. Among authors: beck jf. Oncol Rep. 2006 Nov;16(5):1047-52. Oncol Rep. 2006. PMID: 17016591

8

Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma.

Kumar KS, Sonnemann J, Hong le TT, Buurman C, Adler F, Maass M, Völker U, Beck JF. Kumar KS, et al. Among authors: beck jf. Anticancer Res. 2007 Jan-Feb;27(1A):465-70. Anticancer Res. 2007. PMID: 17352268 Free article.

9

Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells.

Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong le TT, Klier U, Bröker B, Völker U, Beck JF. Sonnemann J, et al. Among authors: beck jf. J Cancer Res Clin Oncol. 2007 Nov;133(11):847-58. doi: 10.1007/s00432-007-0227-8. Epub 2007 May 8. J Cancer Res Clin Oncol. 2007. PMID: 17486365

10

Synergistic activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid and the bisphosphonate zoledronic acid against prostate cancer cells in vitro.

Sonnemann J, Bumbul B, Beck JF. Sonnemann J, et al. Among authors: beck jf. Mol Cancer Ther. 2007 Nov;6(11):2976-84. doi: 10.1158/1535-7163.MCT-07-0221. Mol Cancer Ther. 2007. PMID: 18025282

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters